知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

736 条记录 (耗时 0.027 秒)

    Solid preparation
    1.
    发明授权
    Solid preparation 有权

    公开(公告)号：US10350170B2

    公开(公告)日：2019-07-16

    申请号：US15553852

    申请日：2016-02-25

    申请人： Takeda Pharmaceutical Company Limited

    发明人： Ikuro Yamane ,  Yukihiro Nomura ,  Yutaka Nishimoto ,  Wataru Hoshina

    IPC分类号： A61K9/36 ,  A61K9/20 ,  A61K31/519 ,  A61K47/10 ,  A61K47/14 ,  A61K47/34 ,  A61K9/28

    摘要： Provided is a solid preparation showing improved stability of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea and a salt thereof in the solid preparation, and a method of stabilizing the compound in a solid preparation.A tablet containing not less than 25 mass % of the compound; a solid preparation containing (1) the compound, and (2) a fat and oil-like substance having a low melting point, which is selected from polyethylene glycol, glycerol monostearate and triethyl citrate; a method of stabilizing the compound in a tablet, including adding not less than 25 mass % of the compound; and a method of stabilizing the compound, including adding a fat and oil-like substance having a low melting point, which is selected from polyethylene glycol, glycerol monostearate and triethyl citrate to a solid preparation containing the compound.

    Oral formulation of anhydrous olanzapine form I
    5.
    发明授权
    Oral formulation of anhydrous olanzapine form I 有权
    无水奥氮平口服制剂I

    公开(公告)号：US08962018B2

    公开(公告)日：2015-02-24

    申请号：US12159030

    申请日：2006-12-19

    申请人： Ignacio Diez Martin ,  Carmen Ubeda Perez ,  Pablo Pablo Alba

    发明人： Ignacio Diez Martin ,  Carmen Ubeda Perez ,  Pablo Pablo Alba

    IPC分类号： A61K9/28 ,  A61K9/36 ,  A61K31/55 ,  A61K31/551

    CPC分类号： A61K9/284 ,  A61K31/551

    摘要： The invention relates to a solid formulation for the oral administration of olanzapine that comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable excipients, said core being coated with a functional polymer that acts as filmogenic agent. The method for obtaining it comprises: i) providing anhydrous olanzapine Form I or a salt thereof and, optionally, pharmaceutically acceptable excipients in solid form; ii) providing a functional polymer that acts as filmogenic agent; iii) preparing a dispersion of said functional polymer in an aqueous medium,—and applying the dispersion obtained in step iii) onto the solid form of step i).

    摘要翻译： 本发明涉及用于口服奥氮平的固体制剂，其包含无水奥氮平形式I或其药学上可接受的盐的核心，以及任选的药学上可接受的赋形剂，所述核心用作为成膜剂的功能性聚合物涂覆。 获得它的方法包括：i）提供无水奥氮平I型或其盐和任选的固体形式的药学上可接受的赋形剂; ii）提供充当成膜剂的功能聚合物; iii）将所述官能聚合物在水性介质中的分散体制备，并将步骤iii）中得到的分散体加到步骤i）的固体形式上。